OvaScience Reports Second Quarter 2016 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported its second quarter 2016 financial results and highlighted recent accomplishments.

“Following our equity offering in June, which raised net proceeds of approximately $53.9 million, we are in a strong financial position to further expand access to the AUGMENT treatment and to advance the development of OvaPrime and OvaTure,” said Harald Stock, Ph.D., President and Chief Executive Officer of OvaScience.

Back to news